FY2026 Earnings Estimate for Ardelyx Issued By HC Wainwright

Posted by George Bondi on Nov 6th, 2026

Ardelyx, Inc. (NASDAQ:ARDX – Free Report) – Analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Ardelyx in a research report issued to clients and investors on Wednesday, November 4th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings of ($0.18) per share for the year, up from their previous forecast of ($0.26). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ardelyx’s Q4 2026 earnings at $0.04 EPS, FY2027 earnings at $0.06 EPS, FY2029 earnings at $1.18 EPS and FY2030 earnings at $1.58 EPS.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ardelyx in a research report on Friday, September 25th. Citigroup reduced their price objective on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Wedbush reissued an “outperform” rating and set a $9.00 target price on shares of Ardelyx in a research report on Tuesday, August 18th. BTIG Research decreased their target price on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Finally, Zacks Research upgraded shares of Ardelyx from a “strong sell” rating to a “hold” rating in a research note on Friday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ardelyx has an average rating of “Moderate Buy” and a consensus price target of $13.90.

Check Out Our Latest Research Report on Ardelyx

Ardelyx Stock Down 9.1%

ARDX stock opened at $2.99 on Friday. The firm has a 50-day simple moving average of $3.37 and a two-hundred day simple moving average of $5.26. Ardelyx has a one year low of $2.95 and a one year high of $8.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 3.45 and a quick ratio of 3.15.

Ardelyx (NASDAQ:ARDX – Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $120.88 million during the quarter, compared to the consensus estimate of $121.03 million. Ardelyx had a negative return on equity of 35.30% and a negative net margin of 11.85%. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.08) earnings per share.

Insider Activity at Ardelyx

In other Ardelyx news, insider John E. Bishop sold 19,750 shares of Ardelyx stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $76,235.00. Following the completion of the sale, the insider directly owned 317,095 shares in the company, valued at approximately $1,223,986.70. The trade was a 5.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Michael Raab sold 58,574 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $226,095.64. Following the completion of the sale, the chief executive officer directly owned 1,619,792 shares in the company, valued at $6,252,397.12. This trade represents a 3.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 126,059 shares of company stock worth $486,588 in the last ninety days. 5.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC lifted its position in Ardelyx by 842.7% during the third quarter. Sterling Capital Management LLC now owns 8,088 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 7,230 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new stake in Ardelyx in the second quarter valued at $35,000. Kestra Advisory Services LLC acquired a new stake in Ardelyx during the 3rd quarter worth about $39,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Ardelyx during the 3rd quarter worth about $44,000. Finally, Vontobel Holding Ltd. acquired a new stake in Ardelyx during the 3rd quarter worth about $46,000. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Ardelyx News Roundup

Here are the key news stories impacting Ardelyx this week:

Positive Sentiment: Ardelyx reported third-quarter EPS of $0.00, ahead of analysts’ expectation of a $0.02 loss. Product revenue was $125.5 million, while total revenue of $127.66 million came in slightly below estimates; revenue grew 21% year over year. The company maintained its 2026 IBSRELA revenue outlook of $350 million to $370 million. Ardelyx Q3 earnings
Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to $0.04 from $0.01 and its FY2026 estimate to a loss of $0.18 per share from a loss of $0.26. The firm kept its Buy rating and $13 price target. TD Cowen also reaffirmed its Buy rating. TD Cowen rating
Neutral Sentiment: The company completed enrollment in its Phase 3 ACCEL trial of IBSRELA for adults with chronic idiopathic constipation, an operational milestone ahead of future trial updates. ACCEL trial enrollment
Negative Sentiment: HC Wainwright cut its EPS forecasts for FY2027, FY2029 and FY2030, including a reduction for FY2029 to $1.18 from $1.56. The longer-term estimate revisions temper the improvement in its near-term outlook.
Negative Sentiment: Multiple law firms publicized a securities class action against Ardelyx, with a November 16 lead-plaintiff deadline. The lawsuit alleges the company misrepresented payer access and reimbursement barriers affecting IBSRELA and XPHOZAH; these claims are allegations, not established findings. Litigation adds uncertainty and reputational risk. Class action allegations

Ardelyx Company Profile

(Get Free Report)

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.